Joseph A. Dearani: HCM and congenital heart surgery
HCM, apical aneurysm and complex congenital reconstruction · Rochester, Minnesota, United States
Research by Yevhenii Kozlov · Co-Founder of BookimedUpdated 8 October 2026Sources linked throughout
At a glance
Joseph Dearani’s Mayo practice spans HCM, Ebstein anomaly, congenital surgery and complex reoperations. Mayo’s selected apical-myectomy research addresses a different problem from routine basal septal obstruction.
Distinct HCM phenotypes
Mayo describes septal and selected apical myectomy pathways; apical aneurysm repair may accompany a transapical operation.
The 2000–2020 centre cohort studied transapical myectomy plus aneurysm repair; estimated five-year survival was 94.5%, with median follow-up 4.9 years.
The apical study concerns selected patients with aneurysms and is coauthored programme evidence. It does not mean that all apical or nonobstructive HCM requires surgery.
The Mayo series covers transapical myectomy plus apical aneurysm repair between 2000 and 2020. Median follow-up was 4.9 years; reported estimated five-year survival was 94.5%.
How to interpret this: This selected retrospective programme cohort is not an individual surgeon score. It does not establish that all apical or nonobstructive HCM requires surgery.
Mayo Rochester’s surgical scope includes septal and selected apical myectomy, congenital valve reconstruction and repeat operations. Dearani’s practice connects HCM with Ebstein anomaly and paediatric/adult congenital surgery.